18 July 2025VideosAmericasJohn Rearick, Dechert | Michael Penn, BlueRock Therapeutics | Mark Stewart, Merck | Paul Fleming, Seaport Therapeutics | Robin Weatherhead, Ventus Therapeutics
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
Experts from Dechert, BlueRock Therapeutics, Merck, Seaport Therapeutics, and Ventus Therapeutics examine the impact of recent court rulings following Amgen v. Sanofi on broad genus claims within life sciences patents, as discussed at LSPN.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
21 May 2026 European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration.
20 May 2026 The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.
19 May 2026 In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".